Roche To Start Phase 3 Study For Alzheimer's Prospect This Year After New Data From Phase 2 Roche's trontinemab data showed dose-dependent amyloid reduction in Alzheimer's patients, while its Elecsys pTau181 test aims for European launch in 2025
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest strain. Large biopharma firms remain protected, while medtech companies navigate potential margin pressures and competitive shifts.
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday? Roche's MUSETTE trial found no additional benefit of high-dose Ocrevus over the 600 mg IV dose, reaffirming its efficacy and safety for relapsing multiple sclerosis.
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option.
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug.
Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global commercialization rights.
Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events.
NovoCure Q4 EPS Misses, Revenue Matches NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.
Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval? Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound.
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating IBD.
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression.
Legal Marijuana Linked To Drop In Anxiety Medications: What It Means For Pharma Giants Medical marijuana reduces benzodiazepine prescriptions, saving patients from potential risks. This threatens big pharma's profits.
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients.
Regeneron Pharmaceuticals Slumps As Sales Of High-Dose Eylea Disappoint The company is also facing off with biosimilars for standard Eylea and competition with Roche.
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed positive Phase 3 results.
Roche CEO Reassures No Job Cuts Despite Challenges: Report Roche Holding AG reportedly says no layoffs planned. CEO Schinecker provides pipeline updates including potential anti-obesity drug by 2029.
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease The drug technically missed the study's primary goal. But there's still promise it could work in specific patients.
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits Prothena and Roche report Phase 2b PADOVA results on prasinezumab in Parkinson's, showing promising trends and nominal significance in key analyses.
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments.
